NCT06178588 - Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2026

Conditions

Locally Advanced CholangiocarcinomaMetastatic CholangiocarcinomaRecurrent CholangiocarcinomaStage III Hilar Cholangiocarcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Hilar Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Interventions

PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

BIOLOGICAL

Sacituzumab Govitecan

Given IV

Trial Locations (1)

66160

RECRUITING

University of Kansas Cancer Center, Kansas City

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Kansas Medical Center

OTHER